Crohn-betegség: vizsgálatok itt: Hollandia

In Hollandia 41 Also abroad 422

41 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.

3. fázisTaking people
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
Where
Amsterdam, Groningen, Nijmegen, Rotterdam, Tilburg, Uden, Utrecht
Életkor
18 év and over
People
567 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2024-518296-56-00 · EU 2024-518296-56-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Where
Amsterdam, Groningen, Nijmegen, Opole, Rotterdam, Tilburg, Uden, Utrecht
Életkor
16 év to 80 év
People
1200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06430801 · EU 2023-508636-61-00
No phaseTaking people
The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.
Where
Amsterdam
Életkor
18 év and over
People
40 worldwide
Run by
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
See details and how to joinNCT06006039
3. fázisTaking people
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Where
Amsterdam, Nijmegen, Rotterdam, Utrecht
Életkor
18 év to 70 év
People
290 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06937099 · EU 2024-520210-21-00
3. fázisTaking people
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Rotterdam
Életkor
2 év to 17 év
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05923073 · EU 2023-504735-41-00
2/3. fázisTaking people
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Where
Amsterdam, Maastricht, Nijmegen, Rotterdam
Életkor
18 év and over
People
1092 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07196722 · EU 2025-521382-27-00
No phaseTaking people
A Prospective Randomised Study of Treatment Selection Based on Epigenetic Markers Versus Standard of Care Treatment Selection in Adults With CROHN's Disease
Where
Almere Stad, Amsterdam, Eindhoven, Maastricht, Nieuwegein, Nijmegen, Tilburg, Utrecht
Életkor
18 év and over
People
378 worldwide
Run by
Alimentiv Inc.
See details and how to joinNCT07363044
3. fázisTaking people
A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease
Where
Maastricht, Nijmegen, Tilburg
Életkor
18 év and over
People
530 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07499232
3. fázisTaking people
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease
Where
Amsterdam, Nijmegen, Rotterdam, Tilburg
Életkor
18 év and over
People
460 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07577843 · EU 2026-525922-39-00
2. fázisTaking people
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Where
Amsterdam, Geleen, Tilburg
Életkor
18 év to 75 év
People
268 worldwide
Run by
Takeda
See details and how to joinNCT06233461 · EU 2023-506704-14-00
3. fázisTaking people
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Amsterdam, Christchurch, Lower Hutt, Nijmegen, Tauranga, Tilburg, Wellington
Életkor
16 év to 80 év
People
980 worldwide
Run by
Sanofi
See details and how to joinNCT07184931
3. fázisTaking people
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
Where
Tilburg
Életkor
16 év to 80 év
People
751 worldwide
Run by
Sanofi
See details and how to joinNCT07184944
3. fázisTaking people
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Where
Amsterdam
Életkor
2 év to 17 év
People
110 worldwide
Run by
AbbVie
See details and how to joinNCT05995353 · EU 2022-502050-14-00
3. fázisTaking people
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Where
Amsterdam, Arnhem, Nijmegen, Sittard-Geleen, Tilburg, Utrecht
Életkor
16 év to 80 év
People
600 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06819878 · EU 2024-513053-69-00
2. fázisTaking people
A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease
Where
Amsterdam, Groningen, Nijmegen, Utrecht
Életkor
18 év and over
People
160 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-525197-19-00 · EU 2026-525197-19-00
No phaseTaking people
Prospective Evaluation of Flare Detection in IBD With Digital Biomarkers: Bring Your Own Device Study
Where
Maastricht, Rotterdam, 's-Hertogenbosch
Életkor
18 év and over
People
600
Run by
Maastricht University Medical Center
See details and how to joinNCT07647640
3. fázisTaking people
A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Where
Nijmegen
Életkor
2 év to 17 év
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06405087 · EU 2023-508804-39-00
3. fázisTaking people
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Where
Rotterdam
Életkor
2 év to 19 év
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT04844606
3. fázisTaking people
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Where
Rotterdam
Életkor
2 év to 17 év
People
90 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT05509777 · EU 2024-511472-32-00
2. fázisTaking people
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Where
Amsterdam, Groningen, Tilburg, Utrecht
Életkor
18 év to 75 év
People
590 worldwide
Run by
AbbVie
See details and how to joinNCT06548542 · EU 2024-513009-30-00
2/3. fázisTaking people
Modafinil for Debilitating Fatigue in Quiescent Inflammatory Bowel Disease MODIFI-IBD Trial)
Where
Arnhem, Nijmegen
Életkor
18 év to 75 év
People
60
Run by
Radboud University Medical Center
See details and how to joinNCT07582458 · EU 2026-525163-41-00
3. fázisTaking people
Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year
Where
Maastricht, Nijmegen, Rotterdam, Tilburg, Utrecht
Életkor
18 év and over
People
302 worldwide
Run by
Janssen Cilag International
See details and how to join2025-521590-13-00 · EU 2025-521590-13-00
No phaseTaking people
PIBD-SETQuality: the Inception Cohort and Safety Registry
Where
Rotterdam
Életkor
0 év to 19 év
People
1500 worldwide
Run by
Erasmus Medical Center
See details and how to joinNCT03571373
3. fázisTaking people
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
Where
Nijmegen
Életkor
2 év to 17 év
People
70 worldwide
Run by
Takeda
See details and how to joinNCT06100289 · EU 2023-503188-40-00
4. fázisTaking people
Methotrexate in paediatric and adolescent Crohn’s disease: an observational study
Where
Amsterdam, Enschede, Groningen, Utrecht
Életkor
Up to 64 év
People
215
Run by
Amsterdam UMC Stichting
See details and how to join2025-524129-42-00 · EU 2025-524129-42-00